{"id":"NCT03954743","sponsor":"GlaxoSmithKline","briefTitle":"Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","officialTitle":"A Phase III, Observer-blind, Randomized, Multi-country Study to Assess the Reactogenicity and Safety of the Porcine Circovirus (PCV) Free Liquid Formulation of GSK's Oral Live Attenuated Human Rotavirus (HRV) Vaccine as Compared to the Lyophilized Formulation of the GSK's HRV Vaccine, When Administered as a 2-dose Vaccination in Infants Starting at Age 6-12 Weeks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-19","primaryCompletion":"2020-11-30","completion":"2020-11-30","firstPosted":"2019-05-17","resultsPosted":"2021-06-18","lastUpdate":"2022-03-10"},"enrollment":1351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Rotavirus"],"interventions":[{"type":"BIOLOGICAL","name":"PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Lyophilized formulation of GSK's oral live attenuated HRV vaccine","otherNames":[]}],"arms":[{"label":"HRV PCV-free Liq Group","type":"EXPERIMENTAL"},{"label":"HRV Lyo group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to complete the total safety database size for GlaxoSmithKline Biologicals' (GSK's) human rotavirus (HRV) vaccine across the Porcine circovirus (PCV)-free development plan.\n\nThis study used a purposely selected lot for PCV-free liquid HRV vaccine that is in the upper range of the usual release potencies. The PCV-free liquid HRV vaccine lots used were stored frozen in order to keep the titer stable until administration during the study.\n\nAs the liquid formulation of GSK's HRV vaccine is not licensed in the US, the lyophilized formulation of the vaccine was used as a control in all phase III studies as part of the PCV-free development plan.","primaryOutcome":{"measure":"Number of Subjects With Any Solicited General Adverse Events (AEs) After the First Vaccination","timeFrame":"During the 8-day follow-up period after the first vaccination (vaccines administered at Day 1)","effectByArm":[{"arm":"HRV PCV-free Liq Group","deltaMin":139,"sd":null},{"arm":"HRV Lyo Group","deltaMin":166,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":37,"countries":["United States","Canada","Hong Kong","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":677},"commonTop":["Irritability","Decreased appetite","Cough","Vomiting","Pyrexia"]}}